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Sm_mary There is a well-known raised risk of leukaemia in children with neurofibromatosis type 1 (NF-1).
We carried out the first detailed population-based study of leukaemia and non-Hodgkin lymphoma (NHL)
associated with NF-I in order to estimate the risk and elucidate the relationship between these conditions.
Over the 17 year study period there were five cases of chronic myelomonocytic leukaemia (CMML) in patients
with NF-1 (relative risk 221; 95% CI 71-514), 12 cases of acute lymphoblastic leukaemia (ALL) (relative nrsk
5.4; 95% CI 2.8-9.4) and five cases of NHL (relative risk 10.0; 95% CI 3.3-23.4). Marrow cytogenetics could
be reviewed for seven patients. Specific abnormalities found were monosomy 21 in a child with CMML and
7p+, 17p- in a child with ALL. No abnormalities were reported of 17q, which includes the NFI gene.
CMML occurred predominantly in boys, who also had a family history of NF-1. ALL and NHL were more
often found in children with no previous family history.
Leukaemia in a child with neurofibromatosis type 1 (NF-1)
was first reported more than 30 years ago (Royer et al.,
1958). Since then there have been numerous other case
reports. The largest series to date was that of Bader and
Miller (1978), who ascertained 12 children with leukaemia
and NF-1 from a group of 16 university hospitals and a
multicentre childhood cancer survey in the USA; to these
they added 17 previously published cases occurring below age
20. Their study was not population based but, as the total
number of cases of leukaemia from only 16 hospitals was
similar to that expected nationally on the basis of incidence
data, it seemed likely that children with NF-I had an overall
increased risk of leukaemia and there was an especially
marked excess of juvenile chronic myeloid leukaemia
(JCML). In a recent investigation of the heritable fraction of
childhood cancer in Britain using data from the population-
based National Registry of Childhood Tumours, the
estimated relative risk of leukaemia in children with NF-1
was 3.8 overall, with a 70-fold excess of chronic myeloid
leukaemia (CML) and a relative risk of 2.7 for acute lym-
phoblastic leukaemia (ALL) (Narod et al., 1991).
The present report concerns the first detailed population-
based study of leukaemia and non-Hodgkin lymphoma
(NHL) associated with NF-1. The purpose of this study was
to estimate the risk of leukaemia and NHL in children with
NF-I and to elucidate the relationship between these condi-
tions in greater detail and on the basis of larger numbers of
cases than in the previous study.
Patients and methods
The National Registry of Childhood Tumours (NRCT)
includes information on children who were domiciled in Eng-
land, Scotland or Wales and aged under 15 at the time of
diagnosis with a malignant neoplasm. The principal sources
of ascertainment are the National Cancer Registration
Schemes, which cover the whole of Britain through a net-
work of regional registries, the register of children under the
care of members of the United Kingdom Children's Cancer
Study Group (UKCCSG), local population-based childhood
cancer registries in several regions, death certificates and
entries to the Medical Research Council leukaemia trials. It
has recently been estimated that, from all these sources com-
bined, the NRCT ascertained 99.5% of all children in Britain
with leukaemia or non-Hodgkin lymphoma (NHL) diag-
nosed during 1974-83 (Stiller et al., 1991). During 1981-84,
over three-quarters of children in Britain with these diag-
noses were registered with UKCCSG (Stiller, 1988), and in
more recent years the proportion is believed to exceed 85%.
Details of major congenital abnormalities, including NF-1,
are obtained about 5 years after diagnosis for children who
have survived and about 1 year after death for those who
have died. Details of abnormalities are also recorded on the
registration form for children in the UKCCSG Register.
Information on cancers, congenital abnormalities and genetic
diseases in other family members is also given on the
UKCCSG registration or obtained at follow-up. These data
are less likely to be complete, however, except for malignant
neoplasms occurring in sibs during childhood, whose records
are linked in the NRCT. In many children with NF-1, no
overt features of the disease appear in the first few years of
life, whereas the peak incidence of leukaemia in childhood is
at age 2-4. Therefore, in an effort to improve ascertainment,
we also asked consultants in all UKCCSG centres to let us
know of any patients with leukaemia or NHL who had
subsequently been found to have NF-1. Nevertheless, it still
seems likely that some cases will have been missed in children
who did not have visible signs of NF-1 at the time of
diagnosis of their leukaemia.
Diagnosis of acute leukaemia or NHL was based on local
morphological review and the results of immunophenotyping,
usually supplemented by central diagnostic review carried out
for the Medical Research Council (MRC) leukaemia trials
and UKCCSG NHL studies. The diagnosis and classification
of chronic leukaemia and myelodysplasia in childhood is at
present unsatisfactory (Chessells, 1991), but we attempted to
assign a morphological diagnosis on the basis of the
French-American-British (FAB) classification (Bennett et
al., 1982).
For both diagnostic groups, reports of cytogenetic studies
were obtained for review in cases where these had been done.
Relative risks were calculated by dividing the observed
numbers of cases of NF-I among patients with each type of
leukaemia or lymphoma by the expected number, assuming
the childhood population prevalence of NF-I of 1:2,558,
which was estimated by Huson et al. (1989) in their study of
NF-I in south-east Wales during 1985; their estimate
included an allowance for underascertainment of new muta-
tion cases of NF-l in childhood. Confidence limits associated
with risk estimates were calculated assuming a Poisson dist-
ribution for the number of cases (Haenszel et al., 1962).
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A total of 21 children with NF-I had histologically or
haematologically confirmed leukaemia or NHL diagnosed
during 1976-92.
Myeloid leukaemia
Five children had CMML (Table I), representing 9% of the
58 children registered with this diagnosis during the study
period. Cases 2, 4 and 5 had a previous family history of
NF-1, while cases 1 and 3 had apparently sporadic NF-1.
The relative risk for CMML with NF-I was 221 (95% CI
71-514).
Case was aged under 2 at and had a slightly
raised fetal Hb. She was maintained on 6-mercaptopurine for
5 years but then developed splenomegaly and died following
radiotherapy to the spleen and chemotherapy with busupha
and thioguanine. Cases 2, 3 and 5 all had hepatosno-
megaly and grossly raised fetal Hb, and died within 6 months
of diagsis. Case 4 presented in the neonatal period with
CMML and subsequently developed signs of NF-I; her fetal
Hb was not raised for age at presentation but subsequently
icreased to 42%. This unusual case was treated with mer-
captopurine and steroids and has been previously reported in
detail (Shaw & Eden, 1989). Now on follow-up at the age of
5 she has a perntly abnormal blood film and remains on
the same drugs in low dose.
Cytogenetic reports could be reviewed for three patients.
Case number 4 had monosomy 21 in three metaphases (Shaw
& Eden, 1989), while cases I and 5 were reported as normal.
The less aggressie forms of myellyspLasia are not
gnerally by the national cancer registration system
and have only been routiely notified to the UKCCSG
register since 1990; no cases have so far been in
childn with NF-1. No cases of NF-i were recorded among
the 1,124 dcilden with acute non-lymphocytic lukaemia
(ANLL) or the 89 with adult-type CML.
Lymphoid leukaemia andNHL
Table 1I gives details of the 16 children with ALL or NHL.
Twelve had ALL, of which six were of the common and
three the T-cell phenotype. Five had NHL, inclulding one
child with T-cell lymphoma who had previously had common
ALL. Of the rmnaining four cases of NHL, two were typed
as T cell and one as B cell. One child with ALL (cas 8) also
had patent ductus arteriosus and Rubinstein-Taybi syn-
drome, and one with NHL (case 20) had ptosis. No further
congenital abnormalites were noted in any other patient.
During the study period, 12/5,725 (0.2%) childen rei
with ALL and 5/1,275 (0.4%) with NHL had NF-1, giving
relative risk estimates of 5.4 (95% CI 2.8-9.4) and 10.0
(95% CI 3.3-23.4) respectively.
Seven of the 16 children with ALL or NHL had a history
of NF-I in other family members. Cases 17-19 are members
of a large sibship with parents who are first cousins; this
family is being reported in greater detail elewhere. Case 8
had a sib with NF-1 and astrocytoma, and ca 11 had a sib
with NF-I and medulloblastoma.
The child with ALL and multiple congenital abnormalities
(case 8) received no active treatment for her leukaemia, and
the lymphoma in case 20 was only diagnosed post mortem.
The remaining children with ALL and NHL were all treated
according to standard protocols. Six of the 11 chiklren
treated for ALL have died, but these included three who had
T-cell ALL diagnosed more than 9 years ago.
Cytogenetic reports could be reviewed for four patients
(cases 10, 11, 12 and 16). Case number 10 was reported as
7p+, 17p-. In two cases (12 and 16), though abnormal, the
poor quality did not allow detaied analysis. Case number 11
had no abnormality. None of the three children with abnor-
mal cytogaentics and ALL had any family history of NF-1.
NF-i is an autosomal dominant genetic condition which
confers an increased risk of a wide range of cancers (Hope &
Mulvihll 1981). Although gliomas and neurofibrosarcomas
are the most frequent malignant complfictions of NF-1, it is
well known that there is also an elevated risk of leukaemia,
and particularly of chronic myeloid leukaemia (Bader &
Milkr, 1978; Narod et al., 1991). From the present study,
there is a 200-fold risk of CMML in children with NF-i and
no evidence for an increased risk of adult, Philadelphia
chromosome-postive CML or of ANLL. For both ALL and
NHL, the results are conistent with a 5-fold to 10-fold risk
in association with NF-1. These relative risks should prob-
ably be regarded as minimum estimates since, as mentioned
above, although ascertainment of cancer in the NRCIT is
vitually complete it is likely that some cases of NF-I have
been missed. The risk estimate for NHL may well have been
inflated by the presence of three cases from a single family,
but it should also be noted that we excuded another child
with NF-i and presumed NHL as this patient's lymphoma
was diagnosed on clinical and radiological grounds alone and
was never confirmed histological.
Bader and MIller (1978) did not apply strict criteria for
differential dias of ANLL and myelodysai CMML
in childhood has, however, long been recognised as a
separate entity, distinguishable from adult CML and from
ANLL (Hardisty et al., 1964). Caial cases, often described
as JCML, have raised fetal Hb and other characteristics of
fetal haemopoiesis, rsistance to chemotherapy and poor sur-
vival (C 1991). At least three of our cases, namely 2,
3 and 5, fall into this typical pattern, as do other reported
cases, e.g. Mays et al. (1980). These additional clnical
ngs are not seen in all chiklden with morphological
CMML, and younger patients in particular tend to have a
better survival (Castro-Malasna et al., 1984), thus resem-
bling our cas 4 and possibly cas 1. A second, distinct group
of patients was subsequently identified who have paeiatric
myeloyspabsia, usually CMML, in association with mono-
somy 7; these tend to be infants without a grossly raised fetal
Hb (Sieff et al., 1981). NE-l has been described both in
patients with this infantile monosomy 7 syndrome and in
others with myelodysplasia who develop monosomy 7 with
evolution of their disease (Kaneko et al., 1989; Shannon et
al., 1992). It is of interest that we found no cases of
monosomy 7 as chiklden with this disorder progrssng to
acute leukaemia would have been reglstered. According to
the retrospectve survey of Blani and Lange (1981), over
10% of chikhden with ANLL may have had a preeukaemic
syndrome, and it is plausible that some of the previously
published children diagnosed over 15 years ago with ANLL
Table I Chiklren with neurofibromatosis and CMML
Age at Follow-up
dinosis Year of Fetal Hb Parent Survival
Case no. Sex (year, month) d&anosis (%) with NF-1 Status (year, month)
1 F 1.9 1980 2.3 No Dead 5,11
2 M 4,10 1981 50 Mother Dead 0,5
3 M 3,10 1982 23.7 No Dead 0,4
4 F 0.1 1987 21 Father Alive 5,3
5 M 2,10 1988 52 Father Dead 0,1NEUROFIBROMATOSIS AND LEEUKAEMIA 971
Table II Children with neurofibromatosis and ALL or NHL
Case no. Sex
6 M
7 F
8 F
9 M
10 M
11 M
12 F
13 M
14 F
15 M
16 F
17 M
F
M
M
18
19
20
21
Age at
diagnosis
(y-ear, month)
2,2
12,3
7,6
3.1
1,3
6,6
2,0
3.6
14,6
9,11
9,9
7.8
4,1
1,6
13,7
Year of
diagnosis
1976
1979
1981
1980
1983
1986
1988
1988
1976
1977
1984
1985
1988
1992
1980
M 7,2 1991
Leukaemial
lYmphoma
type
ALL
ALL
ALL
Common ALL
Common ALL
Common ALL
Common ALL
Common ALL
T-ALL
T-ALL
T-ALL
(i) Common ALL
(ii) T-NHL
T-NHL
T-NHL
Mixed
centroblastic/
centrocytic NHL
B-NHL
I
Parent
with NF-I
No
No
Yes
No
No
Father
No
No
No
Mother
No
Father (
Father
No
Follow-up
Survival
Status (year, month)
Alive 17,9
Dead 2,10
Dead 0,0
Alive 13,0
Dead 4,1
Alive 6,11
Alive 4,4
Alive 4,5
Dead 0,0
Dead 0,5
Dead 1,10
Dead 6,11
Dead
Alive
Dead
Alive
1,1
1,2
0,0
1,11
in association with NF-1 (McEvoy & Mann, 1971; Bader &
Miller, 1978) in fact had infantile monosomy 7.
A previous study suggested that astrocytomas occurring in
people with NF-1 may be unusually aggressive (Ilgren et al.,
1985), but there is no obvious indication from the present
series that leukaemia or NHL associated with NF-1 has a
particularly poor prognosis.
The increased risk of leukaemia in NF-1 is enigmatic
because it is one of the few malignancies associated with
NF-I that does not primarily involve cells derived from the
neural crest. Bader and Miller (1978) suggested that the
association might be elucidated by further study of the clonal
status of leukaemias in NF-1 and a search for chromosomal
abnormalities. Shannon et al. (1994) have recently demon-
strated loss of heterozygosity of the NFI allele in the bone
marrow of five out of nine children with NF-I and
myelodysplasia or ANLL, indicating that NFI acts as a
tumour suppressor in myeloid cells. Cytogenetic studies were
available for review in a disappointingly low proportion of
patients in the present study, though this is partly a reflection
of the length of time since the earliest cases were diagnosed,
and with improvements in cytogenetic methodology much
better information would be expected from a prospective
study. The only specific clonal abnormality reported in a
child with ALL involved deletion of 17p, on which the p53
tumour-suppressor gene is located. Deletions of 17p have
previously been found in neurofibrosarcomas associated with
NF-l (Menon et al., 1990).
The predominance offamilial NF-1 in children with JCML
and higher proportion of apparently sporadic NF-1 in those
with ALL agree with the findings of Bader and Miller (1978).
In a review of children with NF-I and myeloproliferative
disease, Shannon et al. (1992) found that inheritance of NF-1
was maternal in 16 (76%) and paternal in five (24%) of 21
cases: for JCML alone the proportions were 12/17 (71%)
maternal and 5/17 (29%) paternal. In our series the propor-
tion with maternal inheritance of NF-1 was substantially
lower, and the most recent series of Shannon et al. (1994)
contained roughly equal numbers of children with maternal
and paternal inheritance.
There has been one previous report of three cases of T-cell
NHL occurring with NF-I in a single sibship (Kaplan et al.,
1982), but that family differed in several respects from the
one reported here: there was no evidence of consanguinity in
the parents; none of the affected patients developed a second
malignant neoplasm, but the maximum survival time from
diagnosis of NHL was only 8 months; one of the three sibs
also had features of familial polyposis coli. Pratt et al. (1988)
reported two other families in which NHL occurred in con-
junction with NF-I and polyposis coli; both were found to
have consanguinity, though in one the common ancestor was
five generations earlier. Immunophenotype of the lymphomas
was not reported, but one was mediastinal, and thus prob-
ably T cell. It seems likely that the family of cases 17-19 in
the present series is affected by the same syndrome, though
polyposis coli has not yet been detected.
In conclusion, the association of inherited NF-1 with
myeloproliferative disease in boys suggests a multistep pro-
cess of leukaemogenesis (Shannon et al., 1992). The recent
results of Shannon et al. (1994) indicate that the NFl allele
acts as a tumour suppressor in myeloid cells, though several
of their cases showed no loss of heterozygosity. Further
elucidation of this point may be provided by a prospective
study of cases of this extremely rare combination of diseases
which will be facilitated by the national childhood mye-
lodysplasia registry. There is so far no evidence that abnor-
malities of the NFl gene account for the raised risk of
lymphoid malignancy in NF-1, but one of our patients had a
deletion of 17p, including the p53 tumour-suppressor gene.
We intend to review any future cases of leukaemia or NHL
in children with NF-1 in order to detect possible cytogenetic
abnormalities.
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